Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort)

Acute Hidrosadenitis Clinical Trial

— COVER  

Official title:

Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the COVER Cohort (Verneuil Cohort)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04352036
• Other study ID #: RC19_0418
• Status: Recruiting
• Start date: January 4, 2022
• Est. completion date: February 20, 2030

Study information

• Verified date: January 2022
• Source: Nantes University Hospital
• Contact: Brigitte Dreno, PU-PH
• Phone: 0240083118
• Email: brigitte.dreno[@]wanadoo.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Our primary objective with this cohort will be to define the different phenotypes of acute hidrosadenitis, the characterization of which is essential to define suitable therapeutic approaches. Indeed, our recent data allow us to note that there would be different phenotypes of acute hidrosadenitis and therefore different pathologies inducing different follow-ups and care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 465
• Est. completion date: February 20, 2030
• Est. primary completion date: February 20, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patient diagnosed with acute hidrosadenitis by a dermatologist
• Patient agreeing to be part of the study

Exclusion Criteria:

• No affiliation to a social security scheme
• Major under guardianship
• Protected persons

Related Conditions & MeSH terms

• Acute Hidrosadenitis
• Hidradenitis

Intervention

Other:
• no interventional study
no interventional study

Locations

Country	Name	City	State
France	CHU Angers	Angers
France	Chru Brest	Brest
France	CHD Vendée	La Roche Sur Yon
France	CH La Rochelle	La Rochelle
France	CH	Le Mans
France	CH bretagne sud	Lorient
France	CHU de Nantes - Dermatologie	Nantes
France	Chr D'Orléans	Orléans
France	CHU Milétrie	Poitiers
France	Ch de Cornouaille	Quimper
France	CHU Pontchaillou	Rennes
France	Ch Saint-Brieuc	Saint-Brieuc
France	CHRU Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Description of the natural history and identification of the different clinical forms of acute hidrosadenitis	history of the disease, classification of Hurley, Canoui-Poitrine and van der Zee and Jemec	through study completion, an average of 3 years
Primary	Prevalence of severe forms (grade II, III)	Number of patients with severe disease (grades II and III)	through study completion, an average of 3 years
Primary	Definition of different phenotypes of acute hidrosadenitis	patient history, Canoui-Poitrine and van der Zee and Jemec classification, blood and urine tests, imaging	through study completion, an average of 3 years
Primary	Identify the environmental factors associated with the chronicity of the disease	socio-demographic data	through study completion, an average of 3 years
Primary	Identify the environmental factors associated with the chronicity of the disease	questionnaire for collecting dietary habits	through study completion, an average of 3 years
Primary	Identify the environmental factors associated with the chronicity of the disease	biological nutritional assessment research for a dysmetabolic syndrome	through study completion, an average of 3 years
Primary	Identify the environmental factors associated with the chronicity of the disease	research for a dysmetabolic syndrome	through study completion, an average of 3 years
Primary	Identify the environmental factors associated with the chronicity of the disease	lifestyle questionnaire assessing the impact on quality of life	through study completion, an average of 3 years
Primary	Involvement of innate immunity in the development of this chronic inflammation with skin biopsies for bacteriological samples	skin biopsies of a closed nodule and axillary and inguinal bacteriological samples	through study completion, an average of 3 years
Primary	Determine the impact of vitamin D deficiency on inflammatory bowel disease	skin biopsies of a closed nodule and axillary and inguinal bacteriological samples	through study completion, an average of 3 years
Primary	Determine the impact of IGF1 deficiency on inflammatory bowel disease	skin biopsies of a closed nodule and axillary and inguinal bacteriological samples	through study completion, an average of 3 years